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ABSTRACT
Introduction: Comparative data on the burden of
atopic dermatitis (AD) in adults relative to the general population are limited. We performed a large-scale evaluation of the burden of disease among
US adults with AD relative to matched non-AD
controls, encompassing comorbidities, healthcare
resource utilization (HCRU), and costs, using
healthcare claims data. The impact of AD disease
severity on these outcomes was also evaluated.
Methods: Adult AD patients in the Commercial
(n = 83,106), Medicare (n = 31,060), and
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Medi-Cal (n = 5550) databases were matched
(1:1) to non-AD controls by demographic characteristics. AD patients were stratified by disease
severity (higher, lower) using treatment as a
surrogate measure of severity. The comorbidity
burden, HCRU, and costs were evaluated during
a 12-month follow-up period.
Results: In the Commercial, Medicare, and
Medi-Cal populations, patients with AD had a
significantly higher overall comorbidity burden
(P\0.0001), an increased risk of asthma and
allergic rhinitis (both P\0.0001), higher HCRU
(P\0.05), and higher mean total per patient
costs (Commercial: US$10,461 versus US$7187;
Medicare: US$16,914 versus US$13,714; MediCal;
US$19,462
versus
US$10,408;
all
P\0.0001), compared with matched non-AD
controls. Higher disease severity was associated
with an increased comorbidity burden
(P\0.0001), HCRU (P\0.05), and total costs
(Commercial: US$14,580 versus US$7192;
Medicare: US$21,779 versus US$12,490; MediCal;
US$22,123
versus
US$16,639;
all
P\0.0001) relative to lower severity disease.
Conclusion: In this large-scale, healthcare
claims database analysis, AD patients had a
significantly higher comorbidity burden,
HCRU, and costs compared with matched
non-AD controls. Higher disease severity was
associated with an even greater comorbidity
and economic burden.
Funding: Sanofi and Regeneron Pharmaceuticals, Inc.
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INTRODUCTION
Atopic dermatitis (AD) is a chronic skin disorder,
characterized
by
immune-mediated
inflammation, intense itching, and eczematous
lesions [1]. In most cases, AD first occurs in
infants and children [2, 3], and while the disease often resolves by puberty [3, 4], in about
50% of patients AD persists into adulthood and
becomes a chronic, lifelong condition [5, 6].
However, AD can also present for the first time
in adults (adult-onset AD) [7–9]. The estimated
overall lifetime prevalence of AD in US adults is
3.2% [10].
Topical corticosteroids are the established
first-line anti-inflammatory treatment for AD;
however, calcineurin inhibitors, non-steroidal
anti-inflammatory agents, are an alternative
topical treatment option [11–13]. Adult patients
with moderate-to-severe disease (20–46% of
patients [14–18]), whose symptoms are generally not well controlled with topical therapy,
can be treated with short-term (4–8 weeks)
phototherapy in the form of ultraviolet radiation [13]. In the event that topicals and/or
phototherapy fail to control the disorder, systemic immunosuppressants (cyclosporine, azathioprine, methotrexate, or mycophenolate
mofetil) are prescribed. However, the efficacy of
these agents is based on inconsistent supporting
evidence from clinical trials; moreover, they are
associated with a substantial risk of severe
adverse effects [11–13]. Thus, immunosuppressants are not approved for the treatment of AD
in the USA and are typically used off-label.
Systemic corticosteroids are also used for rescue
treatment of moderate-to-severe AD patients
despite limited high-quality evidence supporting the efficacy and safety of these agents in the
treatment of AD [11–13, 19].
Several studies have shown that adult AD is
associated with a substantial patient burden,
including an increased prevalence of atopic
comorbidities (asthma, nasal, and food

allergies) and neuropsychiatric conditions
(anxiety, depression, sleep disturbance), as well
as reductions in work productivity and
health-related quality of life [20–24]. However,
there remains a lack of comparative data on the
burden of AD in adult patients relative to the
general population in the USA. To that end, the
primary objective of this analysis was to
undertake a large-scale evaluation of the disease
burden among US adults with AD relative to
matched non-AD controls, encompassing
comorbidities, healthcare resource utilization
(HCRU), and healthcare costs. The secondary
objective was to evaluate the impact of AD disease severity on these outcomes.

METHODS
Data Sources
Patient-level data were extracted from the
OptumÒ (Eden Prairie, MN, USA) Commercial
and Medicare databases, and the Medi-Cal
database. The Commercial and Medicare insurance claims databases contain patient demographic information, inpatient admission
records, use of outpatient services and prescription drugs, and costs of services. Medi-Cal
contains patient demographics, information on
inpatient and outpatient care, and prescription
drug usage for low-income and disabled California residents. In compliance with the 1996
Health Insurance Portability and Accountability
Act, the databases consist of fully de-identified
datasets, to protect the identities of both
patients and data contributors.
The study conformed with the Helsinki
Declaration of 1964, as revised in 2013, concerning human and animal rights; and Springer’s policy concerning informed consent has
been followed.
Study Design
Commercial and Medicare Data
The study period ranged from January 1, 2010
through September 30, 2015. For each AD
patient, the first physician diagnosis of AD
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(ICD-9-CM code 691.8) during the identification period was the index event, and the date of
this first diagnostic claim was defined as the
index date. The index event identification period ranged from June 30, 2010 through
September 30, 2014, and patient data were
assessed until the end of the study (Fig. 1). The
baseline period was defined as the 6-month
period prior to the index date; the follow-up
period was defined as the 12-month period after
the index date.
Medi-Cal Data
The study period ranged from January 1, 2010
through December 31, 2014. The index event
identification period ranged from June 30, 2010
through December 31, 2013. The baseline and
follow-up periods were as described for the
Commercial and Medicare data (Fig. 1).
Analysis Populations
AD Cohort
Adult AD patients [Commercial: C18 years;
Medicare: C65 years; Medi-Cal: 18–64 years (on
the index date)] were included if they had at
least one diagnostic medical claim for AD during the index event identification period, and
continuous medical and pharmacy enrollment
during the 6-month baseline period through
the 12-month follow-up period. Patients with
missing values for sex, age, race, or region
(Commercial and Medicare) were excluded.

Fig. 1 Sample selection in the Commercial, Medicare, and
Medi-Cal populations. For atopic dermatitis (AD)
patients, the index date was deﬁned as the date of the

1991

AD Severity Subgroups
AD patients were stratified by treatment, which
was used as a surrogate measure of severity
because of the lack of clinical assessment of
disease severity in these databases. The higher
disease severity subgroup comprised patients
who had at least one medical or pharmacy
claim for systemic corticosteroids, systemic
immunosuppressants, or phototherapy during
the 12-month follow-up period. The lower disease severity subgroup comprised patients who
did not receive any claims for systemic corticosteroids, systemic immunosuppressants, or
phototherapy, and had only received topical
corticosteroids or topical calcineurin inhibitors,
or had no treatment for AD during the
12-month follow-up period.
Non-AD Control Cohort
Adults with no medical diagnosis of AD during
the entire study period were randomly assigned
the index date within the index event identification period. Those with continuous medical
and pharmacy enrollment during the 6-month
baseline and 12-month follow-up period were
included in the non-AD control cohort. Patients
with missing values for sex, age, race, or region
(Commercial and Medicare) were excluded.
Matching of AD Patients and Non-AD Controls
AD patients were matched (1:1) with non-AD
control patients by demographic characteristics
[age, sex, race, region (Commercial and

ﬁrst diagnostic claim of AD; for non-AD controls, it was
randomly assigned within the index event identiﬁcation
period
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Medicare); age, sex, race (Medi-Cal)] and index
year. If more than one control patient matched
a particular AD patient, then one of the matched controls was randomly selected to be
included in the matched analysis population. If
no matched control patient was available, then
the AD patient was excluded from the matched
analysis population.

(outpatient ? inpatient ? pharmacy).
Only
costs incurred by payers were included in the
analyses; patient co-payments and non-allowed
charges were excluded. Costs were adjusted to
2014 prices for Medi-Cal data and 2015 prices
for Commercial and Medicare data using the
annual medical care component and drug costs
component of the Consumer Price Index to
reflect inflation.

Comorbidities
Statistical Analyses
Comorbid variables were evaluated during the
12-month follow-up period. Overall comorbidity burden was measured using the Deyo-modified Charlson Comorbidity Index (CCI) score
calculated by assigning a weight ranging from 1
to 6 based on the adjusted risk of mortality for
each of 17 conditions. The sum of the weights
results in an overall comorbidity score, with
higher scores indicating higher risks of mortality [25–27]. In addition, the prevalence of the
following 18 prespecified comorbidities were
measured, including ‘‘atopic march’’ conditions
(asthma, allergic rhinitis, food allergy); other
respiratory conditions (chronic pulmonary disease, chronic rhinosinusitis), other AD-related
conditions (allergic urticaria, autoimmune disorders, conjunctivitis, esophagitis, nasal
polyps); infections (bacterial, viral, and fungal
infections); psychological conditions (attention
deficit hyperactivity disorder, anxiety, depression, sleep disorders), and obesity. These conditions have been previously shown to be
associated with AD [28, 29].
Healthcare Resource Utilization
All-cause HCRU was evaluated during the
12-month follow-up period for the following
categories: inpatient visits, emergency room (ER)
visits, outpatient visits, pharmacy prescriptions,
and specialist (allergist/dermatologist) visits.
Healthcare Costs
Direct healthcare costs were evaluated during
the 12-month follow-up for the following categories: outpatient costs, inpatient stay costs,
pharmacy costs, ER costs, and total costs

Comorbidities
The burden of comorbidities was modeled using
logistic regression, including the calculation of
odds ratios (ORs) with 95% confidence intervals
(CIs). The dependent variable was the presence/
absence of comorbidities; independent variables
included patient demographic characteristics
and non-AD-related comorbidities.
Healthcare Resource Utilization
HCRU data were modeled using logistic regression. In particular, conditional logistic regression was performed among 1:1 matched AD and
non-AD cohorts. Dependent variables included
binary variables such as any inpatient, outpatient, ER, and pharmacy visits; independent
variables included patient demographic characteristics and non-AD-related comorbidities.
Count variables were analyzed with negative
binomial regression. To account for correlation
between matched pairs, a generalized estimating equation was used.
Costs
To estimate adjusted cost differences between
matched cohorts and disease severity groups,
multivariate two-part regression models were
used. Specifically, the estimated cost was calculated by multiplying the probability of having a nonzero cost (first part of the model) by
the predicted nonzero cost values (second part
of the model). In these models, the dependent
variables were inpatient costs, outpatient costs,
ER costs, pharmacy costs, and total costs; independent variables included all patients’ demographic characteristics and non-AD-related
comorbidities.
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RESULTS
Analysis Populations
Flowcharts of adult AD patients and non-AD
controls, and higher and lower severity AD
patients are shown in Fig. 2. After 1:1 matching
of AD patients to non-AD controls, the Commercial AD cohort comprised 83,106 patients
(higher severity, 35.7%; lower severity, 64.3%);

1993

the Medicare AD cohort 31,060 patients (higher
severity, 40.4%; lower severity, 59.6%); and the
Medi-Cal AD cohort 5550 patients (higher
severity, 21.6%; lower severity, 78.4%).
Baseline Demographics
Given that matching was based on patient
demographics, baseline demographic characteristics were identical between the matched AD

Fig. 2 Flowcharts of: a atopic dermatitis (AD) patients and matched non-AD controls; b AD patients stratiﬁed by disease
severity
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and non-AD controls across the three insurance
populations (Table 1). Baseline demographics
were similar for AD patients with higher and
lower disease severity (Table 2).

Treatment Patterns
Treatment pattern data for AD patients in the
Commercial, Medicare, and Medi-Cal insurance
cohorts is shown in Table 3. In line with current
guidelines, the majority of AD patients
(60–72%) were treated with topical corticosteroids; however, 24–26% of patients received
no treatment of any kind. With regard to systemic therapy, 21–40% of patients were treated
with systemic corticosteroids, and approximately 1% received systemic immunosuppressants, with methotrexate accounting for
50–90% of immunosuppressant use.

Comorbidity Burden
Compared with non-AD controls, patients with
AD had a significantly higher overall comorbidity burden in all three insurance populations, as indicated by mean (SD) Deyo-modified
CCI scores (Supplementary Table 1): Commercial, 0.46 (1.10) versus 0.34 (0.98); Medicare,
1.92 (2.21) versus 1.75 (2.21); Medi-Cal, 0.78
(1.48) versus 0.52 (1.37) (all P\0.0001). AD
patients with higher disease severity had an
even larger comorbidity burden relative to
lower severity patients (Supplementary Table 2):
Commercial, 0.63 (1.28) versus 0.37 (0.97);
Medicare, 2.18 (2.33) versus 1.75 (2.10); MediCal, 1.23 (1.77) versus 0.66 (1.36) (all
P\0.0001).
Figure 3 shows adjusted ORs for prespecified
AD-related comorbidities in AD patients relative
to matched non-AD controls. In the

Table 1 Baseline demographics of matched atopic dermatitis (AD) patients and non-AD controls
Commercial
AD
(n = 83,106)

Medicare
Non-AD
(n = 83,106)

AD
(n = 31,060)

Medi-Cal
Non-AD
(n = 31,060)

AD
(n = 5550)

Age, years, mean
(SD)

43 (14.6)

75 (6.7)

37 (13.7)

Female, n (%)

51,390 (61.8)

18,391 (59.2)

4133 (74.5)

African
American

8847 (10.7)

2247 (7.2)

916 (16.5)

Hispanic

8231 (9.9)

3329 (10.7)

2054 (37.0)

White

55,652 (67.0)

22,401 (72.1)

1252 (22.6)

Asian

5777 (7.0)

1630 (5.3)

1129 (20.3)

Other

4599 (5.5)

1453 (4.7)

199 (3.6)

Northeast

11,097 (13.4)

4414 (14.2)

–

Midwest

16,136 (16.4)

5120 (16.5)

–

South

38,671 (46.5)

9582 (30.9)

–

West

17,166 (20.7)

11,332 (36.5)

5550 (100.0)a

Race, n (%)

US region

AD patients and non-AD controls were matched (1:1) by demographic characteristics
a
The Medi-Cal database contains information about Californian residents only

Non-AD
(n = 5550)
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Table 2 Baseline demographics of atopic dermatitis patients stratiﬁed by disease severity

Age, years,
mean (SD)

Commercial (n 5 83,106)

Medicare (n 5 31,060)

Medi-Cal (n 5 5550)

Higher severity Lower severity
(n 5 29,640)
(n 5 53,466)

Higher severity Lower severity
(n 5 12,546)
(n 5 18,514)

Higher
severity
(n 5 1198)

Lower
severity
(n 5 4352)

39 (13.4)

36 (13.8)

45 (14.3)

42 (14.7)

18,794 (63.4)

32,596 (61.0)

African
American

3293 (11.1)

Hispanic

Female,
n (%)

75 (6.6)

76 (6.8)

7637 (60.9)

10,754 (58.1)

930 (77.6)

3203 (73.6)

5554 (10.4)

959 (7.6)

1288 (7.0)

187 (15.6)

729 (16.8)

2932 (9.9)

5299 (9.9)

1396 (11.1)

1933 (10.4)

432 (36.1)

1622 (37.3)

White

20,435 (68.9)

35,217 (65.9)

9076 (72.3)

13,325 (72.0)

328 (27.4)

924 (21.2)

Asian

1462 (4.9)

4315 (8.1)

569 (4.5)

1061 (5.7)

211 (17.6)

918 (21.1)

Other

1518 (5.1)

3081 (5.8)

546 (4.4)

907 (4.9)

40 (3.3)

159 (3.7)

Northeast

3160 (10.7)

7937 (14.8)

1516 (12.1)

2898 (15.7)

–

–

Midwest

5953 (20.1)

10,183 (19.1)

1973 (15.7)

3147 (17.0)

–

–

15,590 (52.6)

23,081 (43.2)

4511 (36.0)

5071 (27.4)

–

Race, n (%)

Region, n (%)

South
West
a

4924 (16.6)

12,242 (22.9)

4328 (34.5)

7004 (37.8)

1198 (100.0)

–
a

4352 (100.0)a

The Medi-Cal database contains information about Californian residents only

Commercial (Fig. 3a) and Medicare (Fig. 3b)
populations, all 18 evaluated AD-related
comorbid conditions were significantly more
likely to occur in AD patients than in non-AD
controls (P\0.0001); in the Medi-Cal population (Fig. 3c), 16/18 conditions showed a significantly increased risk in in AD patients, with
only nasal polyps and food allergy showing
nonsignificant ORs. AD was associated with an
increased risk of the atopic conditions asthma
(Commercial: OR 2.51; Medicare: OR 1.65;
Medi-Cal: OR 2.78; all P\0.0001) and allergic
rhinitis (OR 3.29, 2.34, 3.84, respectively; all
P\0.0001), the respiratory conditions chronic
pulmonary disease (OR 2.07, 1.28, 2.40; all
P\0.0001) and chronic rhinosinusitis (OR 1.65,
1.49, 2.64; all P\0.0001), and the neuropsychiatric conditions sleep disorder (OR 1.77,
1.50, 2.93; all P\0.0001) and anxiety (OR 1.48,

1.46, 1.83; all P\0.0001). Other comorbid
conditions with a significantly increased risk in
AD patients in all three populations were allergic urticaria (OR 6.79, 7.71, 5.52; all P\0.0001)
and conjunctivitis (OR 2.71, 2.15, and 3.00; all
P\0.0001).
Figure 4 shows adjusted ORs for AD-related
comorbidities stratified by disease severity.
Compared with lower AD severity patients,
patients with higher AD severity had a significantly increased risk of asthma (Commercial:
OR 2.32; Medicare: OR 2.44; Medi-Cal: OR 3.24;
all P\0.0001), allergic rhinitis (OR 1.90, 1.77,
1.93, respectively; all P\0.0001), chronic pulmonary disease (OR 2.32, 2.03, 2.74; all
P\0.0001), and chronic rhinosinusitis (OR
2.29, 1.84, 1.90; all P\0.0001). Other comorbid
conditions with a significantly increased risk in
patients with higher versus lower disease
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Table 3 Treatment regimens of atopic dermatitis patients
Treatment usage, n (%)

Commercial (n 5 83,106)

No treatment

21,271 (25.6)

Medicare (n 5 31,060)

Medi-Cal (n 5 5550)

8121 (26.2)

1306 (23.5)

Phototherapy

821 (1.0)

342 (1.1)

24 (0.4)

Any systemic immunosuppressant

892 (1.1)

403 (1.3)

51 (0.9)

Azathioprine

186 (0.2)

78 (0.3)

4 (0.1)

Cyclosporine

170 (0.2)

25 (0.1)

8 (0.1)

Methotrexate

447 (0.5)

281 (0.9)

29 (0.5)

Mycophenolate mofetil

169 (0.2)

47 (0.2)

13 (0.2)

Any systemic corticosteroid

28,986 (34.9)

12,291 (39.6)

1165 (21.0)

Oral

20,267 (24.4)

7226 (23.3)

976 (17.6)

Injectable

13,792 (16.6)

6738 (21.7)

260 (4.7)

50,593 (60.9)

18,723 (60.3)

3988 (71.9)

11,340 (13.6)

4020 (12.9)

870 (15.7)

9477 (11.4)

3131(10.3)

1135 (20.5)

Medium strength

28,893 (34.8)

11,515 (37.1)

2835 (51.1)

Very high strength

14,659 (17.6)

5754 (18.5)

393 (7.1)

3665 (4.4)

354 (1.1)

59 (1.1)

Tacrolimus

2098 (2.5)

207 (0.7)

37 (0.7)

Pimecrolimus

1687 (2.0)

160 (0.5)

24 (0.4)

Any topical corticosteroid
High strength
Low strength

Any topical calcineurin inhibitor

severity in all three populations were allergic
urticaria (OR 2.89, 3.30, 3.98; all P\0.0001)
and nasal polyps [OR 3.35, 2.39 (P\0.0001,
both), 3.73 (P = 0.02)].
Healthcare Resource Utilization
In all three insurance populations, a significantly greater proportion of AD patients
required ER visits, outpatient visits, and pharmacy prescriptions compared with non-AD
controls (all P\0.05; Supplementary Fig. 1). A
significantly greater proportion of higher
severity patients required inpatient visits
(Commercial, Medicare), ER visits (Commercial,
Medicare, Medi-Cal), pharmacy prescriptions
(Commercial, Medicare), and specialist (allergist/dermatologist) visits (Commercial, Medicare, Medi-Cal) compared with lower severity
patients (all P\0.05; Supplementary Fig. 2).

Across all three populations, AD patients had
a significantly higher mean annual number of
ER visits, outpatient visits, and pharmacy prescriptions than non-AD controls (all P\0.05;
Fig. 5). In the Commercial and Medicare populations, higher severity patients used significantly greater annual mean resources across all
five evaluated categories (inpatient visits, ER
visits, outpatient visits, pharmacy prescriptions,
allergist/dermatologist visits) compared with
lower severity patients (all P\0.05; Fig. 6).
Healthcare Costs
Adjusted mean annual total per-patient costs
were significantly higher in AD patients compared with non-AD controls in all three populations
(Commercial:
US$10,461
versus
US$7187;
Medicare:
US$16,914
versus
US$13,714;
Medi-Cal;
US$19,462
versus
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Fig. 3 Adjusted odds ratios of prespeciﬁed comorbidities in
atopic dermatitis (AD) patients and matched non-AD
controls in: a Commercial, b Medicare, and c Medi-Cal
populations. Variables included in the generalized linear

1997

model: age, gender, race, and non-AD-related comorbidities.
ADHD attention deﬁcit hyperactivity disorder, CI conﬁdence interval

1998

Fig. 4 Adjusted odds ratios of prespeciﬁed comorbidities
stratiﬁed by disease severity in: a Commercial, b Medicare,
and c Medi-Cal populations. Variables included in the
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generalized linear model: age, gender, race, and non-ADrelated comorbidities. AD atopic dermatitis, ADHD attention deﬁcit hyperactivity disorder, CI conﬁdence interval
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US$10,408; all P\0.0001), mainly driven by
outpatient costs and pharmacy prescription
costs (Fig. 7). Corresponding total costs were
also significantly increased for higher versus
lower severity patients (Commercial: US$14,580
versus US$7192; Medicare: US$21,779 versus
US$12,490;
Medi-Cal;
US$22,123
versus
US$16,639; all P\0.0001), again mainly driven
by outpatient and prescription costs (Fig. 8).

DISCUSSION
In this retrospective healthcare claims database
study, we performed a comparative analysis of
the burden of disease in US adult AD patients
relative to matched non-AD controls, encompassing comorbidities, HCRU, and healthcare
costs. In addition, we examined the impact of
AD disease severity on these outcomes. Data
from approximately 240,000 patients in the
Commercial, Medicare, and Medi-Cal insurance
databases were analyzed, representing, to the
best of our knowledge, the largest analysis to
date of the clinical and economic burden associated with AD.
The results showed that relative to matched
non-AD controls, adult patients with AD had a
significantly higher overall comorbidity burden,
and a significantly increased risk of atopic
comorbidities, including allergic urticaria,
allergic rhinitis, and asthma. In addition, there
was a significantly increased risk of atopic conditions in patients with higher severity disease
relative to lower severity disease. This association between AD and atopic comorbidities has
been recognized in previous studies [3, 30, 31],
and is consistent with the ‘‘atopic march’’ concept in which AD precedes the development of
other allergic disorders [32].
In accordance with the high comorbidity burden, overall HCRU was significantly higher in AD
patients compared with non-AD controls, and in
higher severity patients compared with lower
severity patients. The data show that the increased
HCRU was primarily driven by outpatient visits
and pharmacy prescriptions. A recent study of the
burden of AD in US adults, based on data from the
2013 National Health and Wellness Survey
(NHWS) [23], also found that HCRU was higher in
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AD patients compared with non-AD controls.
However, in the NHWS study, the increased
HCRU was driven solely by outpatient visits as
pharmacy utilization was substantially lower than
that seen in the current analysis, with 48% of
patients receiving prescriptions in the NHWS
study compared with 92–99% in the current
study. It should be noted that the NHWS study
was based on self-reported data and it is possible
that pharmacy utilization was under-reported.
The higher HCRU in AD patients relative to
non-AD controls translated to annual mean
incremental per-patient costs of US$3200–3300
in the Commercial and Medicare populations,
and around US$9000 in the Medi-Cal population. To put these costs in perspective, one
study reported that the estimated incremental
per-patient costs incurred by US patients with
psoriasis, another common, chronic skin disorder, are US$2284 [33]. Overall, the cost data
reported here are consistent with those of previous studies showing that AD is associated with
substantial HCRU and healthcare costs [34–36],
and that higher AD severity correlates with
increased HCRU and costs [36, 37].
Given that the higher severity subgroup
comprised patients treated with systemic therapy or phototherapy, it is reasonable to suggest
that most of these patients had moderate-to-severe AD. Thus, the cost difference
between the higher severity subgroup and
non-AD controls (Commercial: US$7393;
Medicare: US$8065; Medi-Cal: US$11,715) is a
good approximation of moderate-to-severe
AD-related costs. By applying the distribution of
US insurance plans (Commercial: 60.9%; Medicare: 17.6%; Medicaid: 21.5% [38]) to these
costs, the mean annual per-person costs incurred by patients with moderate-to-severe AD can
be estimated at US$8438. With 1.6 million
uncontrolled moderate-to-severe AD adult
patients in the USA [10, 18, 39, 40], the total
healthcare costs of uncontrolled moderate-to-severe adult AD in the USA can be estimated at $13 billion.
It can be argued that the cost difference
between the higher and lower severity groups
(Commercial: US$7388; Medicare: US$9289;
Medi-Cal: US$5484) could equate to a potential
cost offset obtained by effectively treating

2000

Fig. 5 Adjusted mean annual number of healthcare visits
and number of prescriptions per patient in AD patients and
matched non-AD controls in: a Commercial, b Medicare,
and c Medi-Cal populations. *P\0.05. Variables included
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in the generalized linear model: age, gender, race,
non-AD-related comorbidities, and region (Commercial
and Medicare only). AD atopic dermatitis, ER emergency
room, N/A not applicable
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Fig. 6 Mean annual number of healthcare visits per patient
stratiﬁed by AD disease severity in: a Commercial, b Medicare, and c Medi-Cal populations. *P\0.05. Variables
included in the generalized linear model: age, gender, race,

2001

non-AD-related comorbidities, and region (Commercial
and Medicare only). AD atopic dermatitis, ER emergency
room

2002

Fig. 7 Adjusted mean annual per-patient healthcare costs
in AD patients and matched non-AD controls in the:
a Commercial, b Medicare, and c Medi-Cal populations.
*P\0.05. Variables included in the generalized linear
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model: age, gender, race, non-AD-related comorbidities,
and region (Commercial and Medicare only). AD atopic
dermatitis, ER emergency room
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Fig. 8 Adjusted mean annual per-patient healthcare costs
stratiﬁed by AD disease severity in: a Commercial,
b Medicare, and c Medi-Cal populations. *P\0.05.
Variables included in the generalized linear model: age,

2003

gender, race, non-AD-related comorbidities, and region
(Commercial and Medicare only). AD atopic dermatitis,
ER emergency room

2004

moderate-to-severe patients with innovative
therapies that reduce their burden to that of
lower severity patients. Similar calculations to
that described above would yield a mean
annual cost offset of US$7314 per person
without considering the costs associated with
new therapies. The cost offset is important in
research evaluating the cost-effectiveness of a
new therapy. A strength of this analysis is its
large, geographically and demographically
diverse sample from three major healthcare
insurance programs in the USA. Thus, the
results presented here are likely to be applicable to the general population of US AD adult
patients. Controlling for the presence of
non-AD-related comorbidities and demographic factors through multivariate analysis
allowed us to more precisely estimate the
comorbidity burden, HCRU, and costs specifically attributable to AD. The matching of AD
patients and non-AD controls was performed
to minimize bias due to demographic characteristics. However, it is possible that some bias
remains because of unobservable characteristics. In addition, matching could have
obscured the effect of demographic-associated
clinical characteristics on comorbidities or
disease severity and thus affected outcomes.
The key limitation of this analysis is that AD
patients were stratified for disease severity by
using treatment as a surrogate measure of
severity rather than an objective clinical measure of severity, such as Severity Scoring of
Atopic Dermatitis [41] or the Eczema Area and
Severity Index [42], because such data are not
available in insurance claims databases.
Accordingly, we cannot rule out the possibility
that variability in treatment patterns between
healthcare providers may have introduced bias
into the analyses. A further limitation is that
only direct healthcare costs were calculated;
indirect costs, including the impact of AD on
work productivity and quality of life, were not
considered in the cost evaluation.

Adv Ther (2017) 34:1989–2006

higher comorbidity burden, HCRU, and
healthcare costs compared with matched
non-AD controls. Higher disease severity was
associated with an even greater clinical and
economic burden. These data suggest an unmet
clinical need for more effective therapies for AD,
especially for those patients with higher disease
severity.
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